ATE520709T1 - Campylobacter-polypeptide und verwendungsverfahren - Google Patents

Campylobacter-polypeptide und verwendungsverfahren

Info

Publication number
ATE520709T1
ATE520709T1 AT04784662T AT04784662T ATE520709T1 AT E520709 T1 ATE520709 T1 AT E520709T1 AT 04784662 T AT04784662 T AT 04784662T AT 04784662 T AT04784662 T AT 04784662T AT E520709 T1 ATE520709 T1 AT E520709T1
Authority
AT
Austria
Prior art keywords
methods
polypeptides
treating
present
campylobacter
Prior art date
Application number
AT04784662T
Other languages
English (en)
Inventor
Darren Straub
Daryll Emery
Original Assignee
Epitopix Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitopix Llc filed Critical Epitopix Llc
Application granted granted Critical
Publication of ATE520709T1 publication Critical patent/ATE520709T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04784662T 2003-09-19 2004-09-20 Campylobacter-polypeptide und verwendungsverfahren ATE520709T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50411903P 2003-09-19 2003-09-19
PCT/US2004/030873 WO2005028665A2 (en) 2003-09-19 2004-09-20 Campylobacter polypeptides and methods of use

Publications (1)

Publication Number Publication Date
ATE520709T1 true ATE520709T1 (de) 2011-09-15

Family

ID=34375448

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04784662T ATE520709T1 (de) 2003-09-19 2004-09-20 Campylobacter-polypeptide und verwendungsverfahren

Country Status (9)

Country Link
US (10) US8329192B2 (de)
EP (1) EP1678316B1 (de)
AT (1) ATE520709T1 (de)
AU (1) AU2004274977B2 (de)
BR (1) BRPI0414267A (de)
CA (1) CA2539074C (de)
ES (1) ES2395022T3 (de)
NZ (2) NZ582566A (de)
WO (1) WO2005028665A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830479A (en) * 1994-02-09 1998-11-03 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
CA2182976C (en) * 1994-02-09 2011-07-12 Daryll A. Emery Active immunization using a siderophore receptor protein
CA2708949C (en) 2001-01-03 2016-03-08 Epitopix Llc. Immunizing compositions and methods of use
CA2339436A1 (fr) 2001-03-15 2002-09-15 Josee Harel Production d'anticorps contre les facteurs de virulence associes aux souches d'escherichia coli aeec, et leur utilisation
AU2004274977B2 (en) * 2003-09-19 2011-06-23 Epitopix, Llc Campylobacter polypeptides and methods of use
WO2006026373A1 (en) 2004-08-25 2006-03-09 Epitopix, Llc Fusobacterium polypeptides and methods of use
DK1848732T3 (en) 2005-01-21 2016-11-14 Epitopix Llc YERSINIA SPP.-POLYPEPTIDES AND METHODS OF USE
CA2597263C (en) 2005-02-14 2017-01-17 Epitopix, Llc Polypeptides from staphylococcus aureus and methods of use
GB0720250D0 (en) * 2007-10-17 2007-11-28 Univ Edinburgh Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof
US9932373B2 (en) 2009-03-23 2018-04-03 Epitopix, Llc Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
WO2012025831A2 (en) * 2010-08-24 2012-03-01 The University Of British Columbia Salmonella vaccine proteins
WO2012167163A2 (en) 2011-06-03 2012-12-06 University Of South Alabama Methods and compositions for detecting endometrial or ovarian cancer
WO2013009843A1 (en) * 2011-07-11 2013-01-17 Camas Incorporated Compositions against bacterial toxins
US8753643B1 (en) 2012-04-11 2014-06-17 Life-Science Innovations, Llc Spray dried compositions and methods of use
CN105209493B (zh) 2013-03-14 2019-05-03 德克萨斯州大学系统董事会 用于诊断和治疗用途的her3特异性单克隆抗体
US10340848B2 (en) * 2013-12-26 2019-07-02 Kaneka Corporation I-V measurement device for solar cell, manufacturing method for solar cell, and solar cell module
WO2016135627A1 (es) * 2015-02-26 2016-09-01 Universidad De Los Andes Péptidos derivados de ompa de e. coli y procedimiento de identificación y obtención de los mismos.
CA2991907A1 (en) 2015-07-10 2017-01-19 Douglas T. Burkhardt Proteins and immunizing compositions containing klebsiella proteins and methods of use
BR112018009319A8 (pt) 2015-11-09 2019-02-26 Epitopix Llc polipeptídeos de fusobacterium e métodos de uso
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
EP3668529A4 (de) 2017-07-20 2021-07-14 Spogen Biotech Inc. Bioaktive polypeptide zur verbesserung des pflanzenschutzes, des wachstums und der produktivität
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
JP2020031557A (ja) * 2018-08-28 2020-03-05 株式会社日立ハイテクノロジーズ 生体分子分析装置
US11082452B2 (en) * 2018-10-15 2021-08-03 Paypal, Inc. Multi-dimensional drift nuance intelligence threat engine

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003792A (en) 1967-07-01 1977-01-18 Miles Laboratories, Inc. Conjugates of acid polysaccharides and complex organic substances
US4033792A (en) * 1974-12-23 1977-07-05 United Technologies Corporation Composite single crystal article
US4167560A (en) * 1977-04-12 1979-09-11 Texas Vet Lab, Inc. Polyvalent shipping fever vaccine
US4748018A (en) * 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
US4530963A (en) * 1982-08-20 1985-07-23 Devoe-Holbein International, N.V. Insoluble chelating compositions
US4452775A (en) * 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4871488A (en) 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US4663161A (en) 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US4681761A (en) * 1985-10-24 1987-07-21 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Major iron-regulated protein of Neisseria gonorrhoeae and its use as vaccine
US4981685A (en) 1986-03-07 1991-01-01 Utah State University Foundation Bacterial extract vaccines for veterinary application
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
EP0287206B2 (de) 1987-03-24 1999-11-24 BTG INTERNATIONAL LIMITED (Company No. 2664412) Impfstoff gegen Pasteurella
US5885589A (en) 1988-04-12 1999-03-23 Intervet International B.V. Pasteurella vaccine
FR2644346B1 (fr) 1989-03-20 1994-05-13 Rhone Merieux Vaccins contre les bacteries septicemiques, preparations d'antigenes de bacteries septicemiques, nouvelles bacteries et vecteurs pour la preparation de ces antigenes ou vaccins
US5292869A (en) 1989-04-27 1994-03-08 The Board Of Governors Of The University Method for isolating and purifying transferrin and lactoferrin receptor proteins from bacteria and the preparation of vaccines containing the same
US5141743A (en) * 1989-04-27 1992-08-25 University Technologies International, Inc. Method for isolating and purifying transferrin and lactoferrin receptor proteins and vaccines containing the same
WO1993021951A1 (en) * 1992-04-27 1993-11-11 Michigan State University Method for producing a bacterial vaccine and novel vaccines produced thereby
US5578314A (en) * 1992-05-29 1996-11-26 The Regents Of The University Of California Multiple layer alginate coatings of biological tissue for transplantation
US5534256A (en) 1992-07-02 1996-07-09 University Of Saskatchewan Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins
US5439808A (en) 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
CA2182976C (en) * 1994-02-09 2011-07-12 Daryll A. Emery Active immunization using a siderophore receptor protein
US5830479A (en) * 1994-02-09 1998-11-03 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
US5663004A (en) * 1994-02-15 1997-09-02 Xerox Corporation Recording sheets containing mildew preventing agents
AU1860095A (en) 1994-03-22 1995-10-09 Pfizer Inc. (pasteurellaceae) antigens and related vaccines
US5538733A (en) * 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US5681736A (en) 1994-10-05 1997-10-28 Antex Biologics, Inc. Methods for producing enhanced antigenic shigella bacteria and vaccines comprising same
US6121037A (en) * 1994-10-18 2000-09-19 Stojiljkovic; Igor Bacterial hemoglobin receptor genes
US6048539A (en) * 1995-11-02 2000-04-11 Connaught Laboratories Limited Lactoferrin receptor protein
US5777324A (en) 1996-09-19 1998-07-07 Sequenom, Inc. Method and apparatus for maldi analysis
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
US6692739B1 (en) * 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
JP2000351735A (ja) * 1999-04-09 2000-12-19 Akzo Nobel Nv カンピロバクターワクチン
US20070259007A1 (en) * 1999-10-19 2007-11-08 Kruzel Marian L Lactoferrin: an adjuvant for vaccines
US6682754B2 (en) 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
US20020061569A1 (en) 2000-03-21 2002-05-23 Robert Haselbeck Identification of essential genes in prokaryotes
ATE513913T1 (de) * 2000-05-10 2011-07-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
AT410173B (de) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
CA2708949C (en) 2001-01-03 2016-03-08 Epitopix Llc. Immunizing compositions and methods of use
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
WO2003020875A2 (en) 2001-06-17 2003-03-13 D-Squared Biotechnologies, Inc. Staphylococci surface-exposed immunogenic polypeptides
US6720160B2 (en) 2001-10-11 2004-04-13 Helica Biosystems, Inc. Method for simultaneous detection of multiple microbial antigens in biological specimens from mastitic animals
CN1261398C (zh) * 2001-10-31 2006-06-28 旭硝子株式会社 含氟二烯化合物及其制造方法
WO2004014417A2 (en) 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine compositions comprising l2 and/or l3 immunotype lipooligosaccharides from lgtb- neisseria minigitidis
AU2003249851A1 (en) * 2002-10-03 2004-04-23 Intercell Ag Use of molecules which interact with the haptoglobin receptor ligand binding
US20050106159A1 (en) * 2003-08-12 2005-05-19 Thompson Stuart A. Campylobacter jejuni outer membrane protein immunogenic composition
AU2004274977B2 (en) 2003-09-19 2011-06-23 Epitopix, Llc Campylobacter polypeptides and methods of use
EP1740604A2 (de) 2004-04-27 2007-01-10 Intercell AG Td-antigene
DK1848732T3 (en) 2005-01-21 2016-11-14 Epitopix Llc YERSINIA SPP.-POLYPEPTIDES AND METHODS OF USE
CA2597263C (en) 2005-02-14 2017-01-17 Epitopix, Llc Polypeptides from staphylococcus aureus and methods of use
US7412743B2 (en) * 2006-08-07 2008-08-19 Chiang-Fen Lin Wiper for an automobile rear-view mirror

Also Published As

Publication number Publication date
US8119147B2 (en) 2012-02-21
US8329192B2 (en) 2012-12-11
US9943581B2 (en) 2018-04-17
US10086059B2 (en) 2018-10-02
US9981026B2 (en) 2018-05-29
US20050186217A1 (en) 2005-08-25
EP1678316B1 (de) 2011-08-17
US20160008450A1 (en) 2016-01-14
CA2539074A1 (en) 2005-03-31
US20100111903A1 (en) 2010-05-06
US9463230B2 (en) 2016-10-11
CA2539074C (en) 2017-11-07
WO2005028665A3 (en) 2006-06-22
US20170080073A1 (en) 2017-03-23
WO2005028665A2 (en) 2005-03-31
EP1678316A2 (de) 2006-07-12
ES2395022T3 (es) 2013-02-07
US9925253B2 (en) 2018-03-27
US20170035872A1 (en) 2017-02-09
NZ582566A (en) 2010-11-26
US9109028B2 (en) 2015-08-18
US20170080072A1 (en) 2017-03-23
US20130071434A1 (en) 2013-03-21
BRPI0414267A (pt) 2006-11-21
US20170080074A1 (en) 2017-03-23
EP1678316A4 (de) 2007-06-27
NZ546601A (en) 2010-07-30
AU2004274977A1 (en) 2005-03-31
AU2004274977B2 (en) 2011-06-23
US20050095682A1 (en) 2005-05-05
US9950052B2 (en) 2018-04-24
US20120003269A1 (en) 2012-01-05

Similar Documents

Publication Publication Date Title
ATE520709T1 (de) Campylobacter-polypeptide und verwendungsverfahren
MX341370B (es) Antagonistas anti - beta7 humanizados y usos para los mismos.
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
ATE515277T1 (de) Zusammensetzungen und verfahren zum beschichten von medizinischen implantaten
TW200732349A (en) Anti-OX40L antibodies and methods using same
BR0307058A (pt) N-óxidos de derivados de n-fenil-2-pirimidina-amina
UA86042C2 (en) Substituted indazole-o-glucosides
NZ542616A (en) P38 inhibitors and methods of use thereof
NO20034056D0 (no) Proliferative sykdommer
EA200600280A1 (ru) Композиции на основе производных липопептидных антибиотиков и способы их применения
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
TW200624426A (en) BACE inhibitors
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
TW200716088A (en) Formulations and methods for treating amyloidosis
TW200700066A (en) Compounds for inhibiting ksp kinesin activity
EP1511472A4 (de) Nützliche verbindungen für die behandlung von anthrax und hemmung des letalen faktors
ATE527280T1 (de) Fluoreszentprotein und chromoprotein
AU2003258176A8 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
MY143382A (en) Aqueous rodenticide formulations
DE60323222D1 (de) Verfahren und zusamensetzungen zum abtöten von sporen
DK1521752T3 (da) Makrocykliske forbindelser til behandling af cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties